CRISPR/Cas9 genetic modification of CYP3A5 *3 in HuH-7 human hepatocyte cell line leads to cell lines with increased midazolam and tacrolimus metabolism

Casey R. Dorr, Rory P. Remmel, Amutha Muthusamy, James Fisher, Branden S. Moriarity, Kazuto Yasuda, Baolin Wu, Weihua Guan, Erin G. Schuetz, William S. Oetting, Pamala A. Jacobson, Ajay K. Israni

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Clustered regularly interspaced short palindromic repeats (CRISPR)/ Cas9 engineering of the CYP3A5 *3 locus (rs776746) in human liver cell line HuH-7 (CYP3A5 *3/*3) has led to three CYP3A5 *1 cell lines by deletion of the exon 3B splice junction or point mutation. Cell lines CYP3A5 *1/*3 sd (single deletion), CYP3A5 *1/*1 dd (double deletion), or CYP3A5 *1/*3 pm (point mutation) expressed the CYP3A5 *1 mRNA and had elevated CYP3A5 mRNA (P < 0.0005 for all engineered cell lines) and protein expression compared with HuH-7. In metabolism assays, HuH-7 had less tacrolimus (all P < 0.05) or midazolam (MDZ) (all P < 0.005) disappearance than all engineered cell lines. HuH-7 had less 1-OH MDZ (all P < 0.0005) or 4-OH (all P < 0.005) production in metabolism assays than all bioengineered cell lines. We confirmed CYP3A5 metabolic activity with the CYP3A4 selective inhibitor CYP3CIDE. This is the first report of genomic CYP3A5 bioengineering in human cell lines with drug metabolism analysis.

Original languageEnglish (US)
Pages (from-to)957-965
Number of pages9
JournalDrug Metabolism and Disposition
Volume45
Issue number8
DOIs
StatePublished - Aug 1 2017

Fingerprint

Clustered Regularly Interspaced Short Palindromic Repeats
Cytochrome P-450 CYP3A
Midazolam
Tacrolimus
Hepatocytes
Cell Line
Point Mutation
Bioengineering
Messenger RNA
Exons

Cite this

CRISPR/Cas9 genetic modification of CYP3A5 *3 in HuH-7 human hepatocyte cell line leads to cell lines with increased midazolam and tacrolimus metabolism. / Dorr, Casey R.; Remmel, Rory P.; Muthusamy, Amutha; Fisher, James; Moriarity, Branden S.; Yasuda, Kazuto; Wu, Baolin; Guan, Weihua; Schuetz, Erin G.; Oetting, William S.; Jacobson, Pamala A.; Israni, Ajay K.

In: Drug Metabolism and Disposition, Vol. 45, No. 8, 01.08.2017, p. 957-965.

Research output: Contribution to journalArticle

@article{62a01400859d46ca973180713c049259,
title = "CRISPR/Cas9 genetic modification of CYP3A5 *3 in HuH-7 human hepatocyte cell line leads to cell lines with increased midazolam and tacrolimus metabolism",
abstract = "Clustered regularly interspaced short palindromic repeats (CRISPR)/ Cas9 engineering of the CYP3A5 *3 locus (rs776746) in human liver cell line HuH-7 (CYP3A5 *3/*3) has led to three CYP3A5 *1 cell lines by deletion of the exon 3B splice junction or point mutation. Cell lines CYP3A5 *1/*3 sd (single deletion), CYP3A5 *1/*1 dd (double deletion), or CYP3A5 *1/*3 pm (point mutation) expressed the CYP3A5 *1 mRNA and had elevated CYP3A5 mRNA (P < 0.0005 for all engineered cell lines) and protein expression compared with HuH-7. In metabolism assays, HuH-7 had less tacrolimus (all P < 0.05) or midazolam (MDZ) (all P < 0.005) disappearance than all engineered cell lines. HuH-7 had less 1-OH MDZ (all P < 0.0005) or 4-OH (all P < 0.005) production in metabolism assays than all bioengineered cell lines. We confirmed CYP3A5 metabolic activity with the CYP3A4 selective inhibitor CYP3CIDE. This is the first report of genomic CYP3A5 bioengineering in human cell lines with drug metabolism analysis.",
author = "Dorr, {Casey R.} and Remmel, {Rory P.} and Amutha Muthusamy and James Fisher and Moriarity, {Branden S.} and Kazuto Yasuda and Baolin Wu and Weihua Guan and Schuetz, {Erin G.} and Oetting, {William S.} and Jacobson, {Pamala A.} and Israni, {Ajay K.}",
year = "2017",
month = "8",
day = "1",
doi = "10.1124/dmd.117.076307",
language = "English (US)",
volume = "45",
pages = "957--965",
journal = "Drug Metabolism and Disposition",
issn = "0090-9556",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "8",

}

TY - JOUR

T1 - CRISPR/Cas9 genetic modification of CYP3A5 *3 in HuH-7 human hepatocyte cell line leads to cell lines with increased midazolam and tacrolimus metabolism

AU - Dorr, Casey R.

AU - Remmel, Rory P.

AU - Muthusamy, Amutha

AU - Fisher, James

AU - Moriarity, Branden S.

AU - Yasuda, Kazuto

AU - Wu, Baolin

AU - Guan, Weihua

AU - Schuetz, Erin G.

AU - Oetting, William S.

AU - Jacobson, Pamala A.

AU - Israni, Ajay K.

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Clustered regularly interspaced short palindromic repeats (CRISPR)/ Cas9 engineering of the CYP3A5 *3 locus (rs776746) in human liver cell line HuH-7 (CYP3A5 *3/*3) has led to three CYP3A5 *1 cell lines by deletion of the exon 3B splice junction or point mutation. Cell lines CYP3A5 *1/*3 sd (single deletion), CYP3A5 *1/*1 dd (double deletion), or CYP3A5 *1/*3 pm (point mutation) expressed the CYP3A5 *1 mRNA and had elevated CYP3A5 mRNA (P < 0.0005 for all engineered cell lines) and protein expression compared with HuH-7. In metabolism assays, HuH-7 had less tacrolimus (all P < 0.05) or midazolam (MDZ) (all P < 0.005) disappearance than all engineered cell lines. HuH-7 had less 1-OH MDZ (all P < 0.0005) or 4-OH (all P < 0.005) production in metabolism assays than all bioengineered cell lines. We confirmed CYP3A5 metabolic activity with the CYP3A4 selective inhibitor CYP3CIDE. This is the first report of genomic CYP3A5 bioengineering in human cell lines with drug metabolism analysis.

AB - Clustered regularly interspaced short palindromic repeats (CRISPR)/ Cas9 engineering of the CYP3A5 *3 locus (rs776746) in human liver cell line HuH-7 (CYP3A5 *3/*3) has led to three CYP3A5 *1 cell lines by deletion of the exon 3B splice junction or point mutation. Cell lines CYP3A5 *1/*3 sd (single deletion), CYP3A5 *1/*1 dd (double deletion), or CYP3A5 *1/*3 pm (point mutation) expressed the CYP3A5 *1 mRNA and had elevated CYP3A5 mRNA (P < 0.0005 for all engineered cell lines) and protein expression compared with HuH-7. In metabolism assays, HuH-7 had less tacrolimus (all P < 0.05) or midazolam (MDZ) (all P < 0.005) disappearance than all engineered cell lines. HuH-7 had less 1-OH MDZ (all P < 0.0005) or 4-OH (all P < 0.005) production in metabolism assays than all bioengineered cell lines. We confirmed CYP3A5 metabolic activity with the CYP3A4 selective inhibitor CYP3CIDE. This is the first report of genomic CYP3A5 bioengineering in human cell lines with drug metabolism analysis.

UR - http://www.scopus.com/inward/record.url?scp=85024407093&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024407093&partnerID=8YFLogxK

U2 - 10.1124/dmd.117.076307

DO - 10.1124/dmd.117.076307

M3 - Article

C2 - 28533324

AN - SCOPUS:85024407093

VL - 45

SP - 957

EP - 965

JO - Drug Metabolism and Disposition

JF - Drug Metabolism and Disposition

SN - 0090-9556

IS - 8

ER -